IDH2 and acute myeloid leukemia: Results from different studies reported that the presence of IDH mutations positively correlates with elevated serum 2-HG levels [65,66] and that a concentration of 2-HG higher than 700 ng/mL can predict the IDH mutational status in AML [65], supporting the relevance of the detection of this metabolite to stratify patients who are eligible for specific therapies.